[1] AMARENCO P，LAVALLéE P C，MONTEIRO

TAVARES L，et al. Five-Year Risk of Stroke after

TIA or Minor Ischemic Stroke[J/OL]. N Engl J Med，

2018 [Epub ahead of print]. https：//doi.org/10.1056/

NEJMoa1802712.

[2] THOMALLA G，SIMONSEN C Z，BOUTITIE

F，et al. MRI-Guided Thrombolysis for Stroke with

Unknown Time of Onset[J/OL]. N Engl J Med，2018

[Epub ahead of print]. https：//doi.org/10.1056/

NEJMoa1804355.

[3] HART R G，SHARMA M，MUNDL H，et al.

Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source[J/OL]. N Engl J Med，

2018 [Epub ahead of print]. https：//doi.org/10.1056/

NEJMoa1802686.

[4] JOHNSTON S C，EASTON J D，FARRANT M，

et al. Clopidogrel and Aspirin in Acute Ischemic

Stroke and High-Risk TIA[J/OL]. N Engl J Med，

2018 [Epub ahead of print]. https：//doi.org/10.1056/

NEJMoa1800410.

[5] WANG Y，WANG Y，ZHAO X，et al. Clopidogrel

with aspirin in acute minor stroke or transient

ischemic attack[J]. N Engl J Med，2013，369（1）：

11-19.

[6] PAN Y，JING J，CHEN W，et al. Risks and benefits

of clopidogrel-aspirin in minor stroke or TIA：Time

course analysis of CHANCE[J]. Neurology，2017，88

（20）：1906-1911.

[7] WANG Y，ZHAO X，LIN J，et al. Association

Between CYP2C19 Loss-of-Function Allele Status

and Efficacy of Clopidogrel for Risk Reduction

Among Patients With Minor Stroke or Transient

Ischemic Attack[J]. JAMA，2016，316（1）：70-78.